These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 36607583)
41. A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab. Khaksar Toroghi M; Bosley J; Powell LM; Zhang Y; Yang F; Pu X; Davis JD; Al-Huniti N CPT Pharmacometrics Syst Pharmacol; 2021 Nov; 10(11):1332-1342. PubMed ID: 34327869 [TBL] [Abstract][Full Text] [Related]
46. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. Adam RC; Mintah IJ; Alexa-Braun CA; Shihanian LM; Lee JS; Banerjee P; Hamon SC; Kim HI; Cohen JC; Hobbs HH; Van Hout C; Gromada J; Murphy AJ; Yancopoulos GD; Sleeman MW; Gusarova V J Lipid Res; 2020 Sep; 61(9):1271-1286. PubMed ID: 32646941 [TBL] [Abstract][Full Text] [Related]
47. Circumventing Cardiovascular Calamities: The Dawn of ANGPTL3 Blockade in Severe Dyslipidemia Management. Namitokov A; Karabakhtsieva K Cardiovasc Hematol Disord Drug Targets; 2024 Jul; ():. PubMed ID: 39039670 [TBL] [Abstract][Full Text] [Related]
48. Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia. Tarugi P; Bertolini S; Calandra S J Biomed Res; 2019 Apr; 33(2):73-81. PubMed ID: 29752428 [TBL] [Abstract][Full Text] [Related]
49. The Citrus Flavonoid Nobiletin Downregulates Angiopoietin-like Protein 3 (ANGPTL3) Expression and Exhibits Lipid-Modulating Effects in Hepatic Cells and Adult Zebrafish Models. Lin CY; Chen PY; Hsu HJ; Gao WY; Wu MJ; Yen JH Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293338 [TBL] [Abstract][Full Text] [Related]
50. ANGPTL3 Deficiency and Risk of Hepatic Steatosis. D'Erasmo L; Di Martino M; Neufeld T; Fraum TJ; Kang CJ; Burks KH; Di Costanzo A; Minicocci I; Bini S; Maranghi M; Pigna G; Labbadia G; Zheng J; Fierro D; Montali A; Ceci F; Catalano C; Davidson NO; Lucisano G; Nicolucci A; Arca M; Stitziel NO Circulation; 2023 Nov; 148(19):1479-1489. PubMed ID: 37712257 [TBL] [Abstract][Full Text] [Related]
51. Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors. Tomlinson B; Wu QY; Zhong YM; Li YH J Lipid Atheroscler; 2024 Jan; 13(1):2-20. PubMed ID: 38299167 [TBL] [Abstract][Full Text] [Related]
52. Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia. Fukami H; Morinaga J; Nakagami H; Hayashi H; Okadome Y; Matsunaga E; Kadomatsu T; Horiguchi H; Sato M; Sugizaki T; Kuwabara T; Miyata K; Mukoyama M; Morishita R; Oike Y Cell Rep Med; 2021 Nov; 2(11):100446. PubMed ID: 34841293 [TBL] [Abstract][Full Text] [Related]
53. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins. Kim K; Ginsberg HN; Choi SH Diabetes Metab J; 2022 Jul; 46(4):517-532. PubMed ID: 35929170 [TBL] [Abstract][Full Text] [Related]
54. ANGPLT3 in cardio-metabolic disorders. Su X Mol Biol Rep; 2021 Mar; 48(3):2729-2739. PubMed ID: 33677817 [TBL] [Abstract][Full Text] [Related]
55. Angiopoietin-like 3 inhibition of endothelial lipase is not modulated by angiopoietin-like 8. Sylvers-Davie KL; Segura-Roman A; Salvi AM; Schache KJ; Davies BSJ J Lipid Res; 2021; 62():100112. PubMed ID: 34461133 [TBL] [Abstract][Full Text] [Related]
56. Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia? Doggrell SA Expert Opin Biol Ther; 2021 Mar; 21(3):299-302. PubMed ID: 33295805 [No Abstract] [Full Text] [Related]